Trexquant Investment LP acquired a new position in Sarepta Therapeutics (NASDAQ:SRPT) in the first quarter, Holdings Channel reports. The institutional investor acquired 7,135 shares of the biotechnology company’s stock, valued at approximately $529,000.
Other institutional investors have also added to or reduced their stakes in the company. LPL Financial LLC acquired a new position in Sarepta Therapeutics in the fourth quarter worth $643,000. Jennison Associates LLC boosted its holdings in Sarepta Therapeutics by 0.6% in the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after purchasing an additional 6,357 shares during the period. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 0.9% in the fourth quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after purchasing an additional 58,433 shares during the period. TimesSquare Capital Management LLC boosted its holdings in Sarepta Therapeutics by 3.5% in the fourth quarter. TimesSquare Capital Management LLC now owns 491,250 shares of the biotechnology company’s stock worth $27,333,000 after purchasing an additional 16,800 shares during the period. Finally, Hall Laurie J Trustee boosted its holdings in Sarepta Therapeutics by 2,430.8% in the fourth quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 3,160 shares during the period. 85.21% of the stock is owned by hedge funds and other institutional investors.
Get Sarepta Therapeutics alerts:
A number of equities analysts have commented on the stock. Credit Suisse Group reaffirmed a “hold” rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, March 12th. Leerink Swann lifted their price objective on shares of Sarepta Therapeutics from $88.00 to $121.00 and gave the stock an “outperform” rating in a report on Tuesday, May 15th. BidaskClub downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 29th. HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, February 12th. Finally, Goldman Sachs boosted their price target on shares of Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a report on Friday. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and a consensus target price of $89.55.
SRPT stock opened at $93.48 on Friday. The stock has a market capitalization of $6.02 billion, a P/E ratio of -57.00 and a beta of 1.34. Sarepta Therapeutics has a fifty-two week low of $28.82 and a fifty-two week high of $95.67. The company has a debt-to-equity ratio of 0.55, a current ratio of 13.37 and a quick ratio of 12.28.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.23). The company had revenue of $64.60 million during the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. The business’s revenue for the quarter was up 295.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) EPS. analysts anticipate that Sarepta Therapeutics will post -1.79 EPS for the current fiscal year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics (NASDAQ:SRPT).